Inhibition of Angiogenesis In Vivo by Interleukin 12

1995727 citationsJournal Article

Authors

Emile E. Voest · Boston Children's Hospital

B. M. Kenyon · Harvard University

M. OʼReilly · Cancer Support Community

Gary A. Truitt · La Roche College

Robert J. D’Amato · Harvard University

Judah Folkman · Harvard University

Abstract

Recognition of the mechanisms of the antiangiogenic properties of IL 12 may be crucial in planning its clinical applications, including a possibility of coadministration with other inhibitors of neovascularization.

Topics & Keywords

Cytokine Signaling Pathways and Interactions Bioactive Compounds and Antitumor Agents Phytochemistry and Bioactive Compounds

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 87, Issue 8, pp. 581-586

DOI: 10.1093/jnci/87.8.581

Field-Weighted Citation Impact: 17.43